

---

## WilmerHale Represents Editas Medicine in \$50M Offering of Common Stock

DECEMBER 11, 2017

On December 6, 2017, Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine from this offering are expected to be approximately \$50 million, before deducting estimated offering expenses. Editas Medicine has granted the underwriter a 30-day option to purchase up to an additional 295,500 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine.

The WilmerHale team representing Editas in this transaction is led by [Rosemary Reilly](#) and includes [Craig Hilts](#), [Ryan Mitteness](#) and [Hilary Baker-Jennings](#).

Read [Editas' press release](#) for more information.